China now leads India 2:1 in clinical trials
This article was originally published in Scrip
China has overtaken India in terms of share of new clinical trials. A ratio of 1:1 China:India in number of new trials in 2008 has been transformed into a 2:1 ratio in 2011. While China has expanded its clinical trial bases in the past 5 years, unpredictable regulations in India and slow approval timelines appear to have significantly hurt India's sector.
You may also be interested in...
A rise in bureaucracy and increased liability for clinical trial sponsors have impacted the popularity of India as a location for pharmaceutical companies’ clinical studies. Trialtrove’s Deborah Jeanfavre examines the data, which show a continuing decrease in new industry-sponsored trials starting in India over the past five years.
Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.